Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
309 stopped studies mapped to Urinary System Adenocarcinoma and descendants · 85% state a reason
Over the 309 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT00485563 | A Phase II Study of EC17 (Folate-hapten Conjugate) in Patients With Progressive… | Phase 2 | terminated | Jun 13, 2007 | Endocyte | Changes in treatment paradigm resulted in a lower than expected rate of accrual. | Enrollment / accrual |
| NCT00561912 | Low Dose Decitabine + Interferon Alfa-2b in Advanced Renal Cell Carcinoma | Phase 2 | terminated | Nov 21, 2007 | M.D. Anderson Cancer Center | Low accrual. | Enrollment / accrual |
| NCT01441388 | A Study Of Crizotinib Plus VEGF Inhibitor Combinations In Patients With Advanced Solid… | Phase 1 | withdrawn | Sep 27, 2011 | Pfizer | Business/Operational issues | Sponsor / business decision |
| NCT00065572 | Exploratory Study to Assess the Biological Activity of ZD6126 in Subjects With Newly… | Phase 2 | suspended | Jul 31, 2003 | AstraZeneca | not stated | Not stated |
| NCT00277316 | Study of XL999 in Patients With Metastatic Renal Cell Carcinoma | Phase 2 | terminated | Jan 16, 2006 | Symphony Evolution, Inc. | Development of XL999 was stopped due to cardiac toxicities in the subjects | Safety / toxicity |
| NCT00491738 | A Study Evaluating the Efficacy and Safety of Sunitinib With or Without Bevacizumab in… | Phase 2 | terminated | Jun 26, 2007 | Genentech, Inc. | Based on the data collected, the combination of bevacizumab and sunitinib appeared to be poorly… | Other (stated, no rule matched) |
| NCT00417677 | A Study Combining Treatment With Temsirolimus and Sunitinib for Subjects With Advanced… | Phase 1 / Phase 2 | terminated | Jan 4, 2007 | Wyeth is now a wholly owned subsidiary of Pfizer | Decision was made not to attempt a lower dose | Other (stated, no rule matched) |
| NCT00131651 | ATN-161 in Advanced Renal Cell Cancer | Phase 2 | terminated | Aug 19, 2005 | Attenuon | not stated | Not stated |
| NCT00151645 | Efficacy of Activated Lymphocytes in Renal Cell Carcinoma. | Phase 2 | terminated | Sep 9, 2005 | Rennes University Hospital | not stated | Not stated |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 22 days agoSource updated Mar 8, 2012source: clinicaltrials